FLT1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This Target Evaluation Report for FLT1 is generated from PatSnap Life Sciences MCP data workflows, combining Target & Disease MCP biology context with Clinical Trials MCP validation and competitive signals.
For AI teams building biomedical agents, PatSnap Life Sciences MCP Servers provide structured retrieval across target biology, disease context, clinical trials, drug evidence, IP intelligence, and other R&D intelligence sources.
65 Direct drug records from Target & Disease MCP | 38 Development records in target context | 648 Disease associations captured | 4798 Clinical trial records from Clinical Trials MCP |
Explore PatSnap Life Sciences MCP Servers for AI agents
Executive View
FLT1 / VEGFR1 is both receptor and regulatory sink for VEGF signaling
Target & Disease MCP profiles FLT1 as VEGFR1, a high-affinity receptor for VEGFA, VEGFB, and PGF. It regulates embryonic vasculature, angiogenesis, macrophage function, chemotaxis, invasion, and can act as a negative regulator or decoy for VEGFA by limiting free ligand availability.
The biology is important but less directly drugged than VEGFA or VEGFR2
The MCP workflow retrieved 65 direct drug records, 38 development records, and 648 disease associations. Clinical Trials MCP returned 4,798 trial records, mostly reflecting pathway-level anti-angiogenic development and multikinase activity.
Competition overlaps with VEGFR pathway programs
Recent examples include zanzalintinib plus pembrolizumab in renal-cell carcinoma, lenvatinib-containing cholangiocarcinoma, and anlotinib bioequivalence work. These trials map the pathway rather than proving FLT1-selective opportunity.
IP and strategy view
FLT1 strategy should focus on ligand trapping, placental/retinal biology, macrophage or invasion contexts, and differentiation from broad VEGF pathway blockade.
Clinical Validation and Competitive Landscape
Clinical Trials MCP returned 4798 registered trial records connected to FLT1. The sample below is used as a directional competitive readout rather than a full regulatory review.
| Trial | Phase | Status |
|---|---|---|
| Zanzalintinib plus pembrolizumab in resectable clear-cell renal-cell carcinoma | Phase 2 | Not yet recruiting |
| RAINBOW lenvatinib-containing regimen in unresectable intrahepatic cholangiocarcinoma | Phase 3 | Not yet recruiting |
| Anlotinib capsule fasting bioequivalence pilot trial | Not Applicable | Not yet recruiting |
R&D Strategy Recommendation
Use FLT1 as a nuanced pathway target rather than a simple kinase-inhibition thesis. The most credible angles are ligand regulation, disease-specific biology, or differentiated anti-angiogenic modality.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
